Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
AFFF Lawsuit Exposure to firefighting foam chemicals may result in an increased risk of cancer for firefighters, military and airport personnel.
Paraquat Parkinson’s Disease Lawsuits Exposure to the toxic herbicide Paraquat has been linked to a risk of Parkinson's disease.
New York AG Calls for More Stringent Warnings for Singulair Pediatric Suicide Risks Many parents are still unaware about the risk of Singulair psychiatric side effects, including pediatric suicide risks, the letter warns. February 29, 2024 Martha Garcia Add Your Comments The popular asthma drug Singulair poses a serious mental health threat to children, increasing their risk of suicide, aggression, and other mental health problems, New York Attorney General Letitia James warns. On February 21, the attorney general sent a letter (PDF) to the U.S. Food and Drug Administration (FDA) calling for changes to be made to Singular’s warning label. The letter indicates that Singulair’s mental health side effects make it a safety risk to children in the U.S. Singulair (montelukast) is an asthma medication that belongs to a class of drugs known as selective leukotriene receptor antagonists. It is widely used among both children and adults, involving a pill taken orally once a day to treat asthma, exercise induced asthma and seasonal allergies. Although most consumers believe the medication is safe and carries few serious side effects, the FDA issued a drug safety communication about the Singulair suicide risks in March 2020, announcing that the strongest label warning possible would be added regarding mental health side effects linked to the drug, including a prominent “black box” containing information about the risk of suicidal thoughts and behavior. However, James says more action should be taken to help protect children amid an ongoing mental health crisis affecting the nation’s youth. Do You Know about… hair dye cancer lawsuits For Salon Professionals Hair dye lawsuits are being pursued for salon professionals who were routinely exposed to hair dye chemicals and diagnosed with bladder cancer or breast cancer. See if you qualify for a hair dye cancer lawsuit settlement. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Do You Know About… hair dye cancer lawsuits For Salon Professionals Hair dye lawsuits are being pursued for salon professionals who were routinely exposed to hair dye chemicals and diagnosed with bladder cancer or breast cancer. See if you qualify for a hair dye cancer lawsuit settlement. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Singulair Mental Health Concerns Concerns over the pediatric suicide risks and other mental health side effects of Singulair date back for at least 10 years. In 2014, an FDA drug advisory committee rejected a proposal to allow Singulair to be sold over-the-counter, based on data from clinical trials highlighting its side effects. That was followed by the 2020 FDA black box warning requirement. The FDA identified 82 cases of “completed suicide” linked to Singulair use at that time. The agency indicated that 45 of those cases involved patients older than 17 years old, 19 cases involved minors 17 years old or younger, and 18 cases where no age was indicated. In 2022, according to FDA-conducted research, children using Singulair for asthma faced a greater risk of suffering from anxiety and insomnia and were more likely to be prescribed antidepressants. Other research has concluded that 62% of pediatric patients using Singulair suffer neuropsychiatric events. Despite the warnings and research, many instances of suicide, aggression, and depression are still reported among pediatric patients using Singulair, the attorney general’s letter notes. “Since that decision in March 2020, the prevalence of tragic adverse mental health events, including aggression, depression, and suicide, continue to be widely reported, and disproportionately so for pediatric patients,” the letter states. “Of the estimated 12 million people prescribed the medication, an estimated 1.5 million are children. The effects of montelukast on children are of particularly urgent concern in light of the national youth mental health crisis plaguing out State and the subsequent strain on our health care system.” Stronger Singulair Side Effects Warnings Needed The letter argues the current black box warning is insufficient, indicating that many parents are still unaware of Singulair pediatric suicide risks. James calls for an updated warning to include language highlighting the specific risks of Singulair mental health side effects, and indicate the benefits of using the asthma medication may not outweigh the risks. The letter also calls for the FDA to conduct new investigations into the medication, as well as send warning letters to doctors, pharmacists, and other healthcare providers warning them about the risks, and to implement other interventions to help prevent more children from suffering Singulair psychiatric side effects. Organon officials have said the company is taking reports of the adverse events seriously. However, a number of Singulair lawsuits have been filed since the black box warning was added, mainly in New Jersey state court, indicating the manufacturer failed to adequately warn patients and health care professionals about the drug’s suicide risks, resulting in serious injuries and deaths. Singulair brought in more than $411 million in sales for Organon in 2022. Tags: Asthma, Asthma Drug, Children, Children Death, Depression, New York, Organon, Singulair, Suicide More Lawsuit Stories Depo-Provera Meningioma Diagnosis Information Required To Qualify for Lawsuit: Order April 1, 2025 Judge Rejects J&J’s Third Bankruptcy Filing, Killing $9B Talcum Powder Settlement April 1, 2025 Igloo Cooler Class Action Lawsuit Filed Over Fingertip Amputation Risks April 1, 2025 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermCommentsThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Depo-Provera Meningioma Diagnosis Information Required To Qualify for Lawsuit: Order (Posted: today) Women pursuing Depo-Provera meningioma lawsuits will have to provide documentary proof of their diagnosis and the versions of the birth control shot they received within 120 days of filing their case. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Lawsuit Timeline for Preparing Pilot Trial Cases Outlined by MDL Judge (03/24/2025)Women Can File Depo-Provera Brain Tumor Lawsuits Directly in MDL: Court Order (03/18/2025)75 Lawyers in Depo-Provera Lawsuits Seek MDL Leadership Roles (03/10/2025) Cartiva SCI Lawsuit Alleges Toe Implant Worsened Pain, Decreased Range of Motion (Posted: yesterday) An Indiana woman has filed a Cartiva SCI implant lawsuit, indicating that the toe implant failed due to a defective design, resulting in the need for revision surgery and recommendations to permanently fuse her big toe. MORE ABOUT: CARTIVA IMPLANT LAWSUITCartiva Implant Injury Lawsuit Set for Trial in February 2026 (03/07/2025)Lawsuit Indicates Cartiva Implant Fails in 2 Out of 3 Patients, But Continued To Be Sold in U.S. (02/13/2025)Cartiva Toe Implant Lawsuit Filed Over Worsened Pain, Reduced Range of Motion and Need for Surgical Removal (02/07/2025) Salon Professionals Claim Occupational Exposure to Hair Dye Products Caused Bladder Cancer: Lawsuits (Posted: 4 days ago) Two California hair stylists filed separate lawsuits, indicating that repeated occupational exposure to toxic chemicals in hair coloring dyes caused them to develop bladder cancer. MORE ABOUT: HAIR DYE LAWSUITHair Color Lawsuit Filed Over Salon Worker’s Bladder Cancer Diagnosis (03/20/2025)Brazilian Blowout Cancer Lawsuit Filed by Missouri Hair Stylists Over Exosure to Toxic Chemicals (03/11/2025)Initial Status Conference for Hair Dresser’s Bladder Cancer Lawsuit Set for May 5 (03/10/2025)
Depo-Provera Meningioma Diagnosis Information Required To Qualify for Lawsuit: Order (Posted: today) Women pursuing Depo-Provera meningioma lawsuits will have to provide documentary proof of their diagnosis and the versions of the birth control shot they received within 120 days of filing their case. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Lawsuit Timeline for Preparing Pilot Trial Cases Outlined by MDL Judge (03/24/2025)Women Can File Depo-Provera Brain Tumor Lawsuits Directly in MDL: Court Order (03/18/2025)75 Lawyers in Depo-Provera Lawsuits Seek MDL Leadership Roles (03/10/2025)
Cartiva SCI Lawsuit Alleges Toe Implant Worsened Pain, Decreased Range of Motion (Posted: yesterday) An Indiana woman has filed a Cartiva SCI implant lawsuit, indicating that the toe implant failed due to a defective design, resulting in the need for revision surgery and recommendations to permanently fuse her big toe. MORE ABOUT: CARTIVA IMPLANT LAWSUITCartiva Implant Injury Lawsuit Set for Trial in February 2026 (03/07/2025)Lawsuit Indicates Cartiva Implant Fails in 2 Out of 3 Patients, But Continued To Be Sold in U.S. (02/13/2025)Cartiva Toe Implant Lawsuit Filed Over Worsened Pain, Reduced Range of Motion and Need for Surgical Removal (02/07/2025)
Salon Professionals Claim Occupational Exposure to Hair Dye Products Caused Bladder Cancer: Lawsuits (Posted: 4 days ago) Two California hair stylists filed separate lawsuits, indicating that repeated occupational exposure to toxic chemicals in hair coloring dyes caused them to develop bladder cancer. MORE ABOUT: HAIR DYE LAWSUITHair Color Lawsuit Filed Over Salon Worker’s Bladder Cancer Diagnosis (03/20/2025)Brazilian Blowout Cancer Lawsuit Filed by Missouri Hair Stylists Over Exosure to Toxic Chemicals (03/11/2025)Initial Status Conference for Hair Dresser’s Bladder Cancer Lawsuit Set for May 5 (03/10/2025)